A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC

  title={A Comprehensive Meta-Analysis of Association between EGFR Mutation Status and Brain Metastases in NSCLC},
  author={Li Tan and Yinying Wu and Xiaowei Ma and Yanli Yan and Shuai Shao and Jiaxin Liu and Hailin Ma and Rui Liu and Linyan Chai and Juan Ren},
  journal={Pathology \& Oncology Research},
Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation have different clinicopathological characteristics compared with EGFR wild type NSCLC. A growing number of studies focused on the relevance between EGFR mutation status and brain metastases (BM) in NSCLC, but it remains controversial. Therefore, this study performed a comprehensive meta-analysis to untangle this issue. Several electronic databases including Pubmed, Embase, Web of science and Cochrane… Expand
Personalized post-surgical care?-possible strategies for NSCLCs with EGFR mutation.
  • K. Suda
  • Medicine
  • Translational lung cancer research
  • 2020
It is proposed that, similar to the advanced-stage setting, personalization will be an important component for this strategy and that personalized post-surgical care will consist of the following three steps: evaluate the personal risks of recurrence, predict the possible metastatic organ(s), and select an appropriate adjuvant therapy for high-risk patients. Expand
Prophylactic Cranial Irradiation reduces brain metastases and improves overall survival in high-risk metastatic non-small cell lung cancer patients: a randomized phase II study (PRoT-BM trial).
This is the first study to evaluate PCI in EGFRm, ALKr or CEA elevated NSCLC patients, showing a significant improvement in CMB, and among a selected high-risk population for developing BM. Expand
The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence
Brain metastases had a similar driver mutational landscape to cutaneous melanomas in TCGA, but KRAS was the most significantly enriched driver gene, with 4/50 (8%) of brain metastases harbouring non-synonymous mutations. Expand
Hotspot KRAS mutations in brain metastases at the first metastatic recurrence of cutaneous melanoma
This analysis, the largest to date, suggests that early metastases to the brain are characterized by significant enrichment of hotspot KRAS mutations, potentially implicating constitutive RAS-driven cellular programs in neurotropic metastatic behavior in these cases. Expand
E2F1-mediated repression of WNT5A expression promotes brain metastasis dependent on the ERK1/2 pathway in EGFR-mutant non-small cell lung cancer.
The role of WNT5A is revealed in NSCLC BM with EGFR mutation, and it is proved that E2F1-mediated repression of W NT5A was dependent on the ERK1/2 pathway, supporting the notion that targeting the ERk1-2-E2F 1-WNT5a pathway could be an effective strategy for treating BM in EGFR-mutant NSCLc. Expand


EGFR mutation status on brain metastases from non-small cell lung cancer.
There is a higher incidence of brain metastases for patients with EGFR+ metastatic NSCLC, even when adjusted for differences in survival, compared to EGFR WT. Expand
Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer
Synchronous BM was more common in NSCLC patients with EGFR MT than in those with EG FR WT, however, EGFR mutations were associated with significantly longer median BM-OS, especially when the brain was the first metastatic site. Expand
Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations
Patients with EGFR-mutated NSCLC were more likely to develop BMs, but apparently also survived longer after BMs; the correlation between epidermal growth factor receptor mutations and BMs among East Asian patients was evaluated. Expand
EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
A significant association between EGFR mutation and risk of brain metastases at the time of diagnosis and follow-up after curative resection for pulmonary adenocarcinoma is found, indicating the distinct clinical features of EGFR-mutated tumors in terms of head metastases. Expand
Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival
While EGFR positive patients with BM at diagnosis had a longer survival, EGFR status had no influence on TTD in patients who developed BM later during the course of disease. Expand
Epidermal Growth Factor Receptor Mutational Status and Brain Metastases in Non–Small-Cell Lung Cancer
There is a nearly two-fold higher incidence of EGFR mutations in NSCLC among patients with brain metastases at diagnosis, andEGFR mutations did not predict for outcomes from brain metastasing. Expand
High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases
This study analyzed the association of epidermal growth factor receptor (EGFR) mutations and BMs in non-small cell lung cancer (NSCLC) to find that NSCLC patients with BMs had a higher incidence of EGFR mutations and those with mutant EGFR had aHigher frequency of BMs. Expand
The correlation between EGFR mutation status and the risk of brain metastasis in patients with lung adenocarcinoma
Among patients with EGFR mutations, those mutated at exon 19 had the highest incidence of brain metastasis (BM), and patients withEGFR mutations are more likely to develop heterochronous BM, while TKIs improved the survival of patients with lung adenocarcinoma and BM who harbored EGFR sensitive mutations. Expand
Impacts of EGFR mutation and EGFR-TKIs on incidence of brain metastases in advanced non-squamous NSCLC
Both the EGFR mutation-positive status and the use of a TKI are associated with higher incidence of brain metastases for patients with advanced non-squamous NSCLC. Expand
A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
The data suggest that EGFR mutation is an independent predictive and prognostic risk factor for BM and a positive predictive factor for OS in patients with BM. Expand